Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 9Neoplasms 7Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Colorectal Neoplasms 5Lymphoma 4Liver Neoplasms 4Lung Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma 2Locally Advanced Rectal Cancer 2Hematologic Diseases 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor, Adult 1

Interventions

parsaclisib 2MLN 8237 2zanidatamab 1tislelizumab 1tanespimycin 1spartalizumab 1sitravatinib 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1cabiralizumab 1Temozolomide 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1HMPL-013 1Capecitabine 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × spartalizumab × Clear all
NCT02678260 2018-06-08

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Completed
18 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡